Familial Amyloid Polyneuropathy Market
Report ID: SQMIG35I3381
Report ID: SQMIG35I3381
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3381 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
172
|Figures:
79
Global Familial Amyloid Polyneuropathy Market size was valued at USD 2.9 Billion in 2024 and is poised to grow from USD 3.14 Billion in 2025 to USD 11.67 Billion by 2033, growing at a CAGR of 8.15% during the forecast period (2026-2033).
The primary driver of the global familial amyloid polyneuropathy (FAP) market is the rapid advancement and commercialization of RNA interference (RNAi) and antisense oligonucleotide (ASO) therapies. Unlike conventional treatments that mainly alleviate symptoms, these innovative therapies suppress transthyretin (TTR) protein production, slowing or preventing amyloid deposition that damages peripheral nerves. As clinical studies continue to demonstrate improved neurological outcomes and longer disease stabilization, physicians are increasingly adopting these disease-modifying therapies. This has encouraged regulatory approvals, greater healthcare investment, and expanded reimbursement, ultimately accelerating market growth while improving long-term patient survival and quality of life.
A key trend driving the global familial amyloid polyneuropathy market expansion is the growing adoption of genetic testing, family screening programmes, and advanced diagnostic technologies for hereditary transthyretin amyloidosis. Because FAP is an inherited disorder, identifying disease-causing TTR mutations in at-risk relatives enables diagnosis before irreversible nerve damage occurs. Earlier diagnosis allows timely initiation of targeted therapies, leading to better clinical outcomes and reduced disability. Consequently, healthcare providers are investing more in specialised diagnostic centres and awareness initiatives, increasing the number of diagnosed patients eligible for advanced therapies and sustaining long-term demand in the global familial amyloid polyneuropathy market.
How is AI Influencing Drug Discovery and Treatment Development in the Familial Amyloid Polyneuropathy Market?
AI is reshaping drug discovery for familial amyloid polyneuropathy by automating target identification, predicting protein folding, and screening virtual libraries at scale. Machine learning models ingest genetic, proteomic and clinical datasets to highlight pathogenic transthyretin variants and suggest stabilizing compounds. These tools shorten the lead optimization cycle and enable adaptive trial designs that match patients to the most promising molecules. In a market where approved options remain few, AI driven platforms give biopharma a competitive edge, accelerating pipeline entry and reducing reliance on costly wet lab experiments. The result is a more agile development landscape that can respond quickly to emerging scientific insights.
In April 2025, Alnylam Pharmaceuticals expanded its use of artificial intelligence and machine learning across RNA interference (RNAi) research to accelerate target identification, biomarker analysis, and clinical development for transthyretin-mediated diseases, including hereditary ATTR amyloidosis with polyneuropathy (familial amyloid polyneuropathy). The AI-driven approach aims to improve precision and shorten development timelines.
Market snapshot - (2026-2033)
Global Market Size
USD 2.9 Billion
Largest Segment
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
Fastest Growth
Mixed Phenotype (Polyneuropathy with Cardiomyopathy)
Growth Rate
8.15% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global familial amyloid polyneuropathy market is segmented by disease type, drug class, route of administration, treatment stage, distribution channel, end user and region. Based on disease type, the market is segmented into hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) and mixed phenotype (polyneuropathy with cardiomyopathy). Based on drug class, the market is segmented into gene silencing therapies, transthyretin (TTR) stabilizers, amyloid-targeting therapies and supportive & symptomatic therapies. Based on route of administration, the market is segmented into intravenous (IV), subcutaneous (SC) and oral. Based on treatment stage, the market is segmented into first-line therapy and subsequent-line therapy. Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, specialty clinics, ambulatory care centers and home healthcare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Based on the global familial amyloid polyneuropathy market growth, gene silencing therapies segment dominates because it directly addresses the underlying pathogenic mechanism of ATTRv PN by reducing hepatic production of mutant transthyretin. This therapeutic approach aligns with physicians’ preference for disease modifying solutions, fostering higher adoption across specialty clinics. The proven clinical efficacy coupled with favorable safety profiles reinforces clinician confidence, driving consistent demand and establishing this class as the market cornerstone in the treatment landscape for patients worldwide today.
However, amyloid-targeting therapies segment emerges as the fastest growing area because novel monoclonal antibodies and small molecules are gaining regulatory approvals that enable direct clearance of deposited amyloid. Heightened clinical interest, expanding pipeline activity and insurer reimbursement optimism accelerate adoption, creating new avenues for market expansion and therapeutic differentiation globally.
Subcutaneous segment dominates because it offers patients a convenient self administered option that reduces hospital visits while maintaining bioavailability comparable to intravenous delivery. The ease of at home dosing aligns with the chronic nature of the disease, encouraging adherence and supporting specialty clinics’ preference for therapies that simplify care pathways. Consequently, providers prioritize subcutaneous formulations, reinforcing their market leadership across the patient community as well as healthcare systems today widely.
On the other hand, oral segment is witnessing the strongest growth momentum because new small molecule TTR stabilizers enable pill based regimens that remove injection discomfort and boost patient quality of life. Clinical evidence, expanding payer support and demand for non invasive therapy accelerate adoption, making oral options a driver of expansion.
To get detailed segments analysis, Request a Free Sample Report
As per the global familial amyloid polyneuropathy market share, North America leads the industry through a combination of advanced healthcare infrastructure, strong research ecosystems, and high adoption of innovative therapies. The United States provides a mature regulatory environment that accelerates approval pathways for rare disease treatments, while extensive specialist networks ensure early diagnosis and comprehensive patient management. Canada contributes with universal health coverage that facilitates patient access to costly biologics and supports collaborative clinical studies across major academic centers. Both nations benefit from robust reimbursement frameworks and active patient advocacy groups that drive awareness and guide policy decisions. Investment from biotech firms and academic partnerships further fuels pipeline development, reinforcing the region’s position as a hub for therapeutic breakthroughs and market leadership. The convergence of these strengths creates a resilient ecosystem that continuously attracts global stakeholders seeking market expansion and clinical excellence.
Familial amyloid polyneuropathy market in the United States benefits from a comprehensive network of tertiary care centers and leading academic hospitals that specialize in rare neuropathies. Patient pathways are supported by diagnostic guidelines that promote early detection, while payer structures enable reimbursement for high‑cost therapies. Strong collaborations between biotech innovators and research institutions accelerate clinical trial enrollment, reinforcing the country’s role as a catalyst for therapeutic advancement and patient‑centric outcomes globally.
Familial amyloid polyneuropathy market in Canada is reinforced by a publicly funded health system that prioritizes equitable access to specialty medicines. Provincial health authorities work closely with clinical experts to streamline pathways for diagnosis and treatment, while national research networks facilitate multicenter studies. Patient advocacy groups play an active role in policy dialogue, ensuring that reimbursement decisions reflect clinical need and promote sustained investment in innovative therapeutic options for patients.
Based on global familial amyloid polyneuropathy regional forecast, Europe experiences rapid expansion of the industry driven by coordinated regulatory frameworks, strong public‑private partnerships, and increasing clinical awareness across member states. The European Medicines Agency offers harmonized pathways that expedite access to orphan therapies, while national health systems invest in specialized referral centers and multidisciplinary care models. Collaborative research consortia leverage genetic registries and patient databases to accelerate biomarker discovery and trial recruitment. Advocacy organizations amplify patient voices, influencing reimbursement policies that balance cost considerations with therapeutic value. The emphasis on real‑world evidence generation further supports payer confidence and informs clinical guidelines, reinforcing the sustainability of market expansion and positioning Europe as a pivotal region for both market growth and scientific leadership.
Familial amyloid polyneuropathy market in Germany is anchored by a robust network of university hospitals that serve as centers of excellence for rare neuropathies. National reimbursement policies facilitate coverage for high‑cost orphan drugs, while the Federal Ministry of Health supports research funding aimed at genetic characterization. Collaborative registries enable systematic patient tracking, and professional societies promote guideline development that standardizes diagnostic and therapeutic approaches across the country and improves outcomes.
Familial Amyloid Polyneuropathy Market in the United Kingdom benefits from an NHS structure that streamlines patient referral pathways to specialist neuropathy clinics. Funding mechanisms encourage adoption of therapies, while the National Institute for Health Research backs projects focused on disease mechanisms. Genetic screening programs are integrated into routine practice, facilitating identification. Patient charities fund awareness campaigns and support services, reinforcing a collaborative ecosystem that advances clinical care and market penetration.
Familial amyloid polyneuropathy market in France is emerging through targeted health‑policy initiatives that prioritize rare disease recognition. Specialized centers within university hospitals provide multidisciplinary care, and the national health insurance scheme ensures reimbursement pathways for orphan medicines. Collaborative research networks link clinicians with biotech firms to explore genotype‑phenotype correlations, fostering clinical development. Patient associations raise disease visibility, shaping legislative advocacy and supporting access to therapeutic options across the healthcare system.
As per global familial amyloid polyneuropathy regional outlook, Asia Pacific is strengthening its position in the industry by leveraging expanding healthcare infrastructure, growing diagnostic capabilities, and increasing regulatory openness to rare disease treatments. Japan’s well‑established clinical research environment supports extensive patient registries and early‑phase trial execution, while South Korea’s rapid adoption of precision medicine frameworks accelerates genotype‑guided therapeutic approaches. Both economies are witnessing heightened awareness among neurologists, leading to earlier identification and referral. Government incentives encourage domestic biotech innovation, resulting in a pipeline of novel agents tailored to regional genetic profiles. Collaborative networks between academic institutions and multinational firms facilitate knowledge exchange, positioning the region as an emerging hub for both clinical advancement and market growth. Increasing patient advocacy activity is also driving policy dialogue, ensuring that reimbursement pathways evolve in step with therapeutic innovation.
Familial amyloid polyneuropathy market in Japan is underpinned by a mature diagnostic ecosystem that integrates imaging and genetic testing within specialist neurology clinics. The national health insurance scheme provides coverage for approved orphan drugs, facilitating patient access. Research initiatives fund translational studies and support clinical trials, fostering collaboration between academia and industry. Patient organizations play a pivotal role in education and advocacy, enhancing disease awareness and supporting timely referral pathways.
Familial amyloid polyneuropathy market in South Korea benefits from precision medicine frameworks that incorporate genetic profiling into routine neuropathy assessment. Reimbursement policies are evolving to accommodate orphan therapies, supported by government subsidies that mitigate cost barriers. Strong collaboration between university hospitals and biotech firms accelerates development of targeted agents, while national patient registries improve epidemiologic understanding. Advocacy groups engage policymakers, ensuring that patient needs inform healthcare financing and access strategies.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Awareness Driving Early Diagnosis
Emerging Gene Therapies Transform Treatment
High Treatment Cost Limits Access
Limited Specialized Centers Restrict Coverage
Request Free Customization of this report to help us to meet your business objectives.
Competition in the global familial amyloid polyneuropathy market outlook intensifies as incumbents pursue strategic M&A, collaborative R&D, and advanced RNA‑targeted platforms. Pfizer’s acquisition of Prothena’s Vyndamax rights and Alnylam’s partnership with AstraZeneca to co‑develop vutrisiran exemplify moves to broaden therapeutic portfolios, while emerging gene‑silencing entrants accelerate pipeline diversification. These actions aim to capture market share and address unmet patient needs across hereditary and wild‑type forms.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global familial amyloid polyneuropathy industry is propelled primarily by rising awareness that fuels earlier diagnosis and expands the pool of eligible patients, while a second powerful driver is the advent of gene‑silencing and RNA‑interference therapies that promise disease‑modifying benefits. North America leads the market thanks to its advanced healthcare infrastructure and rapid regulatory pathways, and within the therapeutic landscape the gene silencing therapies segment holds the largest share because it directly targets the underlying transthyretin pathology. However, the high cost of these innovative treatments remains a major restraint, limiting broader patient access and slowing adoption in cost‑sensitive markets.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 2.9 Billion |
| Market size value in 2033 | USD 11.67 Billion |
| Growth Rate | 8.15% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Familial Amyloid Polyneuropathy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Familial Amyloid Polyneuropathy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Familial Amyloid Polyneuropathy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Familial Amyloid Polyneuropathy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Familial Amyloid Polyneuropathy Market size was valued at USD 2.9 Billion in 2024 and is poised to grow from USD 3.14 Billion in 2025 to USD 11.67 Billion by 2033, growing at a CAGR of 8.15% during the forecast period (2026-2033).
Competition in the global Familial Amyloid Polyneuropathy market intensifies as incumbents pursue strategic M&A, collaborative R&D, and advanced RNA‑targeted platforms. Pfizer’s acquisition of Prothena’s Vyndamax rights and Alnylam’s partnership with AstraZeneca to co‑develop vutrisiran exemplify moves to broaden therapeutic portfolios, while emerging gene‑silencing entrants accelerate pipeline diversification. These actions aim to capture market share and address unmet patient needs across hereditary and wild‑type forms. 'Alnylam Pharmaceuticals Inc.', 'Pfizer Inc.', 'Ionis Pharmaceuticals Inc.', 'BridgeBio Pharma Inc.', 'AstraZeneca plc', 'GlaxoSmithKline plc', 'Sanofi S.A.', 'Novartis AG', 'Takeda Pharmaceutical Company Limited', 'Johnson & Johnson Services Inc.', 'Merck & Co. Inc.', 'Bristol Myers Squibb Company', 'Amgen Inc.', 'F. Hoffmann-La Roche Ltd', 'Eisai Co. Ltd.', 'Biogen Inc.', 'Eli Lilly and Company', 'Sandoz International GmbH', 'Teva Pharmaceutical Industries Ltd.', 'Viatris Inc.'
The expanding public and professional awareness of familial amyloid polyneuropathy encourages earlier clinical suspicion, which leads to timely diagnostic testing and identification of affected individuals before irreversible nerve damage occurs, thereby creating a larger pool of patients eligible for emerging therapeutic options and supporting sustained demand for diagnostic and treatment services across healthcare systems, while also motivating providers to adopt screening protocols, invest in specialist training, and promote patient education initiatives that collectively strengthen market adoption of both existing and pipeline therapies.
Genetic Testing Advances: Rapid improvements in next‑generation sequencing and targeted gene panels are shortening diagnostic timelines for familial amyloid polyneuropathy. Clinicians can now identify pathogenic TTR mutations with greater confidence, enabling earlier therapeutic intervention and personalized care pathways. This diagnostic agility is fostering greater awareness among primary specialists, prompting earlier referral to neurology and cardiology experts. Consequently, patient enrollment in clinical programs is expanding, supporting broader adoption of emerging disease‑modifying agents and reinforcing the market’s growth trajectory through increased physician confidence and payer support.
Why does North America Dominate the Global Familial Amyloid Polyneuropathy Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
